

DEVELOPMENT AND EVALUATION OF FLOATING MICROSPHERES OF OMEPRAZOLE

*Priyanshi Chauhan, Kapil Kumar, Ikram, Aparna Joshi, Deepti Khairya and Deepak Teotia

Department of Pharmaceutics, Global Institute of Pharmaceutical Education and Research, Kashipur- 244713, Uttarakhand, India.

Corresponding Author: Priyanshi Chauhan

Department of Pharmaceutics, Global Institute of Pharmaceutical Education and Research, Kashipur- 244713, Uttarakhand, India.

Article Received on 17/09/2022

Article Revised on 07/10/2022

Article Accepted on 27/10/2022

ABSTRACT

The gastro retentive system prolongs the drug's gastric retention time through staying for many hrs in GIT region. The main aim of the present investigation is to formulate Omeprazole loaded Floating microspheres by spray drying technique. The obtained formulations were evaluated for drug content, entrapment efficiency, Buoyancy time and *in vitro* dissolution studies. The entrapment efficiency was found to be increased by increasing the concentration of the polymer. *In vitro* dissolution studies were conducted for a period of 12 hours. The drug release was continued up to 12 hrs with 99% drug release. From the study it was concluded that formulation with code F4 was yielding the best floating microspheres which were floating for a period of 24 hrs. It decreases drug waste while enhancing the bioavailability and solubility of the medication. These systems possess low density thus remain buoyant for longer time.

KEYWORDS: Omeprazole, floating microspheres, *in vitro* dissolution studies.

INTRODUCTION

The gastro retentive system prolongs the drug's gastric retention time through staying for many hrs in GIT region. It decreases drug waste while enhancing the bioavailability and solubility of the medication. These systems possess low density thus remain buoyant for longer time. These are machines that offer a continuous drug discharge under hydrodynamic control. To make the buoyant systems, granules, powders, capsules, pills, and hollow microspheres were used.^[1-5] The duration of the digestive process ranges from 5 to 2 hours on average.^[6-8]

Solid spherical particles known as microspheres range in diameter in between 1-1000 μm . They, freely-moving sphere shaped biodegradable comprised of different polymers. Due to the extended duration of effective API concentration in the target tissue made possible by the site-specific microparticulate delivery devices, there are less side effects linked to lower plasma concentrations in the peripheral blood circulation.^[9,10] Omeprazole is a selective and irreversible proton pump inhibitor. Stomach acid secretion is decreased as a result of the H⁺/K⁺-ATPase system being inhibited on the secretory membrane of gastric parietal cells. Due to the fact that this enzyme system is also referred to as the acid (proton, or H⁺) pump within the stomach mucosa, omeprazole reduces the last stage of acid production.^[11]

Immediately after oral administration, omeprazole has an inhibitory effect. the greatest impact happens in the first two hours. up to 72 hours can pass between inhibitions without omeprazole.^[12]

The primary goal of the study was to develop and assess omeprazole gastroretentive floating microspheres, which are anticipated to administer the medication in a regulated manner with reduced frequency of drug administration, enhance patient compliance, and increase omeprazole bioavailability.

Preparation of Omeprazole Microspheres

Omeprazole microspheres were produced by spray drying the drug and polymer solutions. The creation of a drug and polymer ethanolic solution was followed by the addition of a cross-linker to the mixture. The following spray drying parameters were established and determined: Feed Rate: 3 ml/min; Cooling Temperature: 900C; Pressure: 2bar; Inlet Temperature: 1300C; Outlet Temperature: 900C. Peristaltic pumps were used to deliver liquid to the nozzle, where the force of compressed air atomized the liquid and broke it up into small droplets. The droplets were blown into a chamber with hot air, where the solvent evaporated and was evacuated via an exhaust tube. A collection bottle was used to collect the dry goods.^[13]

Table 1: Composition of the omeprazole floating microspheres formulations.

| S. No. | Ingredients | Formulation code | | | |
|--------|-------------------------------|------------------|-------|-------|-------|
| | | F1 | F2 | F3 | F4 |
| 1 | Omeprazole | 0.5 g | 0.5 g | 0.5 g | 0.5 g |
| 2 | Ethylcellulose | 0.5 g | 4 g | 0.3g | 0.3 |
| 3 | HPMC E 50 | 0.3g | 0.3g | 4 g | - |
| 4 | PVP | - | 0.3g | - | 0.5 g |
| 5 | Eudragit RS 100 | - | - | - | 0.3g |
| 6 | Ethanol | 15 ml | 15 ml | 15 ml | 15 ml |
| 7 | Dichloromethane | 15 ml | 15 ml | 15 ml | 15 ml |
| 8 | Sodium lauryl sulphate (0.1%) | 100ml | 100ml | 100ml | 100ml |

Evaluation of Microspheres**1. Percentage yield**

Accurate weights of the dried microspheres were used to determine the % yield.^[14-17]

$$\% \text{ yield} = (\text{Practical yield}/\text{Theoretical yield}) \times 100$$

2. Drug content and entrapment efficiency

Microspheres were precisely weighed at 100 mg, ground in a mortar, suspended in 100 ml of phosphate buffer pH-6.8, and then ultrasonically processed for two hours. The samples were then filtered⁴³ and centrifuged for 20 minutes at 1000 rpm to get rid of any supernatant layer. To be spectrophotometrically evaluated at 300 nm, 1 mL of the filtered solution was collected and diluted in 25 mL of phosphate buffer pH-6.8.^[18-20]

Theoretical drug content

$$\frac{\text{Weight of drug - loaded} / \text{Total weight of Microspheres}}{\text{Practical drug content}} \times 100$$

$$\text{Encapsulation efficiency} = (\text{Actual drug content} / \text{Theoretical drug content}) \times 100$$

3. In vitro buoyancy studies

The USP XXIII dissolution apparatus (type II), which was filled with 900 ml of SGF (pH 1.2) containing 0.02 percent tween 20, was covered with the microspheres, each weighing around 0.3 g. A paddle revolving at 100 rpm was used to stir the medium for 12 hours. Microspheres' floating and settling sections were retrieved separately, dried, and weighed.^[21]

4. In-vitro dissolution studies

It was done by the means of USP Paddle Type Equipment. A muslin fabric with 100mg of drug-loaded microspheres was put inside of it, then fastened to the paddle. The buffer is used as a dissolving media in 900 ml. In a dissolution medium with 900 ml of buffer, a precisely weighed sample was added, and it was left to dissolve for up to 12 hours. At regular intervals (every 1 hr), 1 ml of the material was collected and filtered through a 0.4 m membrane filter. Every time a sample was taken, the same 1ml of the dissolving medium was substituted to bring the volume of the dissolution media to 900ml⁴. After that, the materials underwent a 300nm spectrophotometric analysis.^[22-24]

RESULTS**Table 2: Micromeritic Properties of formulations.**

| FORM. CODE | ANGLE OF REPOSE | BULK DENSITY | TAPPED DENSITY | CARR'S INDEX | HAUSNER'S RATIO |
|------------|-----------------|--------------|----------------|--------------|-----------------|
| F1 | 19.42±0.20 | 0.68±0.64 | 0.74±0.73 | 10.1±0.84 | 1.05±0.54 |
| F2 | 25.82±0.80 | 0.41±0.042 | 0.39±0.012 | 9.52±0.026 | 1.078±0.32 |
| F3 | 19.66±0.36 | 0.69±0.62 | 0.73±0.72 | 7.73±0.29 | 1.14±0.011 |
| F4 | 18.66±0.20 | 0.52±0.30 | 0.58±0.36 | 10.1±0.84 | 1.17±0.046 |

Table 3: Evaluation parameters of Omeprazole floating microspheres.

| Code | % Yield | Drug content | Entrapmen efficiency | %Buoyancy |
|------|---------|--------------|----------------------|-----------|
| F1 | 65.9 | 50 | 91.1 | 74.8 |
| F2 | 68.5 | 52.8 | 93.3 | 75.1 |
| F3 | 83.1 | 53.8 | 86.5 | 77.9 |
| F4 | 89.1 | 62.3 | 95.2 | 84.3 |




Figure 1: *In vitro* release profile of Omeprazole floating microspheres.

In the present study four different batches of floating microspheres of curcumin were formulated using different polymer by spray drying. The physical characterization, floating behavior and *in vitro* release studies were studied. Angle of repose, Hausner ratio, and Carr's index can be used to predict flowability. The higher the Hausner ratio the greater the cohesion between particles while the higher the Carr's index of the greater the tendency to form bridges between particles. Floating microspheres of batch F4 were spherical in shape.

Buoyancy for all the formulations was $\geq 74\%$ after 12 h. The nature of the polymer influenced the floating behavior of the microspheres. In general with increase in the amount of polymers there is an increase in the buoyancy percentage. The increase in the buoyancy percentage may be attributed to air which caused swelling because of increased amount of the polymers present. The good buoyancy behavior of the microspheres may be attributed to the hollow nature of the microspheres. Formulations of batch F4 shows more entrapment efficiency. Due their floating nature, the microspheres were forcibly immersed into the dissolution medium to avoid adherence to the surface of the jar, thus leading to nonparticipation in the dissolution process. The drug release was extended to 12 h. Microspheres prepared of batch F4 showed more release (82%).

CONCLUSION

Omeprazole floating microspheres were successfully developed using spray drying method. The microspheres had good yield and showed high, drug entrapment efficiency. The flow properties of microspheres were within the acceptable range and therefore would be easily filled into capsules. Release properties were satisfactory and the formulations hold promise for further

development into drug delivery systems for oral administration of Omeprazole.

REFERENCES

1. Arora, S; Ali, A; Ahuja, A; Khar, RK and Baboota, S. "Floating drug delivery systems: A review", *AAPS PharmSciTech*, 2005; 6(3): 772-90.
2. Nayak AK. Gastroretentive drug delivery systems: a review, *March 2010*; 3(1): 1-9.
3. Verma BK, Pandey S, Arya P. Tablet granulation: current scenario and recent advances. *Universal Journal of Pharmaceutical Research*, 2017; 2(5): 30-35.
4. Vedha Hari B.N.*et al*, The Recent Developments on Gastric Floating Drug Delivery Systems: An overview, *Int .J. PharmTech Res*, 2010; 2(1): 524-534.
5. ALGIN YAPAR E, BESKAN U, KARAVANA SY. A recent overview of locally administered topical otic dosage forms. *Universal Journal of Pharmaceutical Research*, 2019; 4(4): 39-42.
6. Al-kaf AGA, Othman AM. Pharmacosomes: an Updated review, *Universal Journal of Pharmaceutical Research*, 2017; 2(1): 30-33.
7. Kotreka UK, Adeyeye MC, Gastroretentive Floating Drug- Delivery Systems: A Critical Review, *Critical ReviewsTM in Therapeutic Drug Carrier Systems*, 2011; 28(1): 47-99.
8. Peng-Ju Ma, Guo-JunGao,Hai-Gang Chang, Fa-ZhengShen,Lei Hui and Bao- Zhe Jin- Prolonged and Floating Drug Delivery System of Gabapentin for Effective Management of Pain in Spinal Cord Injury -*International Journal of Pharmacology*, 2016; 435-43.
9. Sunday OS. Colon-targeted drug delivery systems: design, trends and approaches. *Universal Journal of Pharmaceutical Research*, 2017; 2(4): 46-50.
10. Kaur G, Paliwal S. Formulation and evaluation of etoricoxib microbeads for sustained drug delivery.

- Universal Journal of Pharmaceutical Research, 2019; 4(1): 35-39.
11. McTavish D, Buckley MM, Heel RC "Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders". *Drugs*, 1991; 42(1): 138–70.
 12. Shirasaka, Y; Sager, J. E.; Lutz, J. D.; Davis, C; Isoherranen, N (July). "Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions". *Drug Metab. Dispos*, 2013; 41(7): 1414–24.
 13. Radwan MA, Abou el Ela AE, Hassan MA, El-Maraghy DA. Pharmacokinetics and analgesic effect of ketorolac floating delivery system. *Drug delivery*, 2015; 22(3): 320-7.
 14. Felix Sunday Yusuf. Formulation and *in-vitro* evaluation of floating microballoons of stavudine. *Universal Journal of Pharmaceutical Research*, 2016; 1(1): 13-19.
 15. Avinash K, Abha D, Praween K, Abhinav G. 11. Floating Drug Delivery System a Significant Tool for Stomach Specific Release of Cardiovascular Drugs. *International Journal of Drug Development and Research*, 2012.
 16. Dubey J, Verma N. Floating drug delivery system: a review. *International Journal of Pharmaceutical Sciences and Research*, 2013; 4(8): 2893-9.
 17. Nayak AK, Malakar J, Sen K K. Gastroretentive drug delivery technologies: Current approaches and future potential. *J Pharm Educ Res*, 2010; 1(2): 1-2.
 18. Anyanwu NCJ, Adogo LY, Ajide B. Development and evaluation of *in situ* gelling gastroretentive formulations of Meloxicam. *Universal Journal of Pharmaceutical Research*, 2017; 2(3): 11-14.
 19. Siswanto A, Fudholi A Nugroho AK, Martono S. In *Vitro* Release Modeling of Aspirin Floating Tablets Using DD Solver Indonesia *Journal of Pharmacy*, 2015; 26(2): 94.
 20. Ikechukwu UR, John Francis DE, Ambi AA. Development and evaluation of Ritonavir hollow microballoons for floating drug delivery. *Universal Journal of Pharmaceutical Research*, 2017; 2(2): 30-34.
 21. Agnihotri, S.A., Jawalkar, S.S., Aminabhavi, T.M. Controlled release of cephalexin through gellan gum beads: Effect of formulation parameters on entrapment efficiency, size, and drug release, *Eur. J. Pharma. Biopharm*, 2006; 63: 249-26. DOI PMid: 16621483.
 22. Saddam C Shaikh, Dnyaneshwar Sanap, Dipak V Bhusari, Shirish Jain, Pooja P Kochar, Vikram N Sanchati. Formulation and evaluation of Ibuprofen gastro-retentive floating tablets. *Universal Journal of Pharmaceutical Research*, 2018; 3(4): 20-25.
 23. Babu VBM., Khar, R.K. *In vitro* studies of sustain release floating dosage forms containing salbutamol sulphate. *Pharmazie*, 1990; 45: 268-270. PMid: 2381979.
 24. Pathak B, Kumar K. Buccal drug delivery system: a tool for the effective delivery of pharmaceuticals. *Universal Journal of Pharmaceutical Research*, 2017; 2(3): 19-24.